- Coordinator
- Helse Stavanger Hf, Norway
- Runs
- 1 November 2023 to 31 October 2027
- Status
- Running
- EU funding
- €8.4m
- Total cost
- €17.6m
- Partners
- 37 organisations in 15 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101132356
What the project is doing
In the project's own words, from its summary on CORDIS.
Alzheimer’s disease (AD) and related disorders leading to dementia are associated with staggering costs and suffering. Recently, there has been some progress in the search for effective therapeutic interventions and it is clear that any treatment is likely to be most effective if administered at the earliest stage of disease, but the health care system is not ready for this new scenario. There is an urgent need, therefore, to establish scalable, cost-efficient diagnostic markers, tools and procedures that can identify people at increased risk, at point of care for stratification into personalized interventions to prevent or delay dementia.
PREDICTOM will develop an open-source, interoperable and customisable biomarker screening platform, utilizing an existing online resource to save time and money, to generate an evidence base for general population screening for AD and related disorders. We will bring diagnostics closer to the patient by examining the feasibility of using samples which can be obtained at home (e.g. finger-prick blood, saliva (for genetics and epigenetics) and stool for microbiom) for diagnostic biomarker analysis.
We will also evaluate innovative technologies for disease risk identification, including digital technologies and novel MRI, EEG, eye tracking, and blood-based biomarkers. The platform will use artificial intelligence models to analyse data from all biomarkers to identify users at high risk of developing dementia and to direct them to personalized intervention to prevent further cognitive decline and development of dementia.
We will seek to facilitate a change in current healthcare practice for early diagnosis of AD through development of new clinical practice guidelines based on evidence generated in the project. By improving the ease of identification of those with early signs of dementia we expect to have a significant impact on personal and financial burden of dementia in Europe and across the world.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Helse Stavanger Hf | Stavanger | Norway | Coordinator |
| Joanneum Research Forschungsgesellschaft Mbh | Graz | Austria | Participant |
| Icometrix NV | Leuven | Belgium | Participant |
| Vrije Universiteit Brussel | Bruxelles / Brussel | Belgium | Participant |
| Universite De Geneve | Geneve | Switzerland | Associatedpartner |
| Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eV | Munchen | Germany | Participant |
| Ge Healthcare GmbH | Dusseldorf | Germany | Participant |
| Klinikum Der Ludwig-Maximilians-Universitat Munchen | Munchen | Germany | Third party |
| Ludwig-Maximilians-Universitaet Muenchen | Planegg | Germany | Participant |
| Siemens Healthcare GmbH | Erlangen | Germany | Participant |
| Siemens Healthineers AG | Forchheim | Germany | Participant |
| Universitatsklinikum Erlangen | Erlangen | Germany | Participant |
| Gn Hearing AS | Ballerup | Denmark | Participant |
| Novo Nordisk A/s | Bagsvaerd | Denmark | Participant |
| Ethniko Kentro Erevnas Kai Technologikis Anaptyxis | Thermi Thessaloniki | Greece | Participant |
| Fundacion Para La Investigacion Del Hospital Universitario La Fe De La Comunidad Valenciana | Valencia | Spain | Participant |
| Neuroelectrics Barcelona SL | Barcelona | Spain | Associatedpartner |
| Starlab Barcelona SL | Barcelona | Spain | Associatedpartner |
| Ge Medical Systems Scs | Buc | France | Third party |
| Qairnel SAS | Bourg-La-Reine | France | Participant |
| Ge Healthcare Magyarorszag Kft | Budapest | Hungary | Third party |
| Pharmacoidea Fejleszto Es Szolgaltato Kft | Szeged | Hungary | Participant |
| Siemens Healthcare Private Limited | Vikhroli East | India | Third party |
| Siemens Healthcare Private Limited | Vikhroli East | India | Third party |
| Alzheimer Europe | Senningerberg | Luxembourg | Participant |
| Stichting Lygature | Utrecht | Netherlands | Participant |
| King's College London | London | United Kingdom | Associatedpartner |
| Muhdo Health Ltd | Ipswich | United Kingdom | Participant |
| National Institute for Health and Care Excellence | Manchester | United Kingdom | Associatedpartner |
| The University of Exeter | Exeter | United Kingdom | Associatedpartner |
| Altoida Inc | Wilmington | United States | Participant |
| Alzpath Inc | Wilmington | United States | Participant |
| Braincheck Inc | Austin | United States | Participant |
| Siemens Healthcare Diagnostics Inc. | Tarrytown | United States | Third party |
| Siemens Healthcare Diagnostics Inc. | Tarrytown | United States | Third party |
| Siemens Medical Solutions Usa Inc | Malvern Pa | United States | Third party |
| Siemens Medical Solutions Usa Inc | Malvern Pa | United States | Third party |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI